SUPER-1 is a 52-week (26-week main phase plus 26-week extension phase), phase 3, treat-to-target trial investigating the efficacy and safety of once-weekly GZR4 versus once-daily insulin glargine U100 ...
Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.
Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.
The FDA just approved Awiqli, a once-weekly insulin treatment for type 2 diabetes. Awiqli allows patients to shift from daily injections. The effectiveness, safety, and side effects are similar to ...
BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating ...
The US Food and Drug Administration has approved insulin icodec (Awiqli), developed by Novo Nordisk, as the first once-weekly long-acting basal insulin for glycemic control in adults with Type ...
SUPER-1 is a 52-week (26-week main phase plus 26-week extension phase), phase 3, treat-to-target trial investigating the efficacy and safety of once-weekly GZR4 versus once-daily insulin glargine U100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results